home :: clinical trials :: treatment trials :: clinical trials
CLINICAL TRIALS 

  AVAILABLE CLINICAL TRIALS
 
Genitourinary Clinical Trials
  Ref # Title
Advanced TCC CALGB 90601 A RANDOMIZED DOUBLE-BLINDED PHASE III STUDY COMPARING GEMCITABINE, CISPLATIN, AND BEVACIZUMAB TO GEMCITABINE, CISPLATIN, AND PLACEBO IN PATIENTS WITH ADVANCED TRANSITIONAL CELL CARCINOMA
High Risk Prostate RTOG 0924 ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL
Advanced Renal CALGB 90802 RANDOMIZED PHASE III TRIAL COMPARING EVEROLIMUS PLUS PLACEBO VERSUS EVEROLIMUS PLUS BEVACIZUMAB FOR ADVANCED RENAL CELL CARCINOMA PROGRESSING AFTER TREATMENT WITH TYROSINE KINASE INHIBITORS
Prostate 1st Line BMS CA184095 RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL TO COMPARE THE EFFICACY OF IPILIMUMAB VS PLACEBO IN ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC PATIENTS WITH METASTATIC CHEMOTHERAPY-NAĎVE CASTRATION RESISTANT PROSTATE CANCER
Bladder RTOG 0712 A PHASE II RANDOMIZED STUDY FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER EVALUATING TRANSURETHRAL SURGERY AND CONCOMITANT CHEMORADIATION BY EITHER BID IRRADIATION PLUS 5-FLUOROURACIL AND CISPLATIN OR QD IRRADIATION PLUS GEMCITABINE FOLLOWED BY SELECTIVE BLADDER PRESERVATION AND GEMCITABINE/CISPLATIN ADJUVANT CHEMOTHERAPY
Prostate, Neo-Adjuvant CALGB 90203 A RANDOMIZED PHASE III STUDY OF NEO-ADJUVANT DOCETAXEL AND ANDROGEN DEPRIVATION PRIOR TO RADICAL PROSTATECTOMY VERSUS IMMEDIATE RADICAL PROSTATECTOMY IN PATIENTS WITH HIGH-RISK, CLINICALLY LOCALIZED PROSTATE CANCER
Prostate SPPORT RTOG 0534 A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPPORT) IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL PROSTATECTOMY
Bladder RTOG 0524 A PHASE I/II TRIAL OF A COMBINATION OF PACLITAXEL AND TRASTUZUMAB WITH DAILY IRRADIATION OR PACLITAXEL ALONE WITH DAILY IRRADIATION FOLLOWING TRANSURETHRAL SURGERY FOR NON-CYSTECTOMY CANDIDATES WITH MUSCLE-INVASIVE BLADDER CANCER
Extensive Prostate Cancer CTSU E3805 This study evaluates the effectiveness of androgen ablation therapy alone compared with chemotherapy plus androgen ablation therapy in patients with metastatic prostate cancer. Androgen ablation therapy—which can be either medical or surgical—stops the production of androgens, which can cause the growth of prostate cancer cells. Androgen ablation therapy can slow the growth of tumors. Patients are randomized into one of the study’s two arms.
 



©2004 MSCCOP & Mount Sinai Medical Center